A 32-year-old woman with anovulatory infertility is being counselled about ovulation induction agents. She has a BMI of 24 kg/m², normal prolactin and TSH levels, and a diagnosis of idiopathic anovulation. Which is the most commonly used first-line agent for ovulation induction in such patients?

Explanation

## First-Line Ovulation Induction Agent **Key Point:** **Clomiphene citrate (CC)** is the most commonly used and most frequently prescribed first-line agent for ovulation induction in anovulatory women with normal prolactin and TSH levels. ### Mechanism of Action Clomiphene citrate is a **selective estrogen receptor modulator (SERM)**: 1. Blocks estrogen feedback at the hypothalamus and pituitary 2. Increases GnRH pulsatility 3. Stimulates FSH and LH secretion 4. Promotes follicular growth and ovulation ### Why Clomiphene Citrate is First-Line | Feature | Clomiphene Citrate | Gonadotropins | Letrozole | |---------|-------------------|---------------|----------| | **Route** | Oral | Parenteral (IM/SC) | Oral | | **Cost** | Very low | High | Low–moderate | | **Monitoring** | Minimal (ultrasound) | Intensive (daily ultrasound + hormones) | Minimal | | **Ovulation rate** | 70–80% | 90–95% | 70–80% | | **OHSS risk** | Low (2–3%) | Moderate–high (5–10%) | Low | | **Multiple pregnancy** | 5–8% (mostly twins) | 20–30% | 3–5% | | **User-friendliness** | Excellent | Poor | Excellent | | **First-line?** | **YES** | Reserved for CC failure | Emerging alternative | **High-Yield:** Clomiphene citrate remains the gold standard first-line agent because it is: - **Oral** (patient compliance) - **Inexpensive** (cost-effective) - **Effective** (70–80% ovulation rate) - **Safe** (low OHSS, low multiple pregnancy risk) - **Requires minimal monitoring** ### Clinical Pearl **Warning:** Do not use clomiphene citrate in: - **Hyperprolactinemia** (must correct first) - **Hypothyroidism** (must correct first) - **Severe male factor** (will not help; needs gonadotropins or ART) - **Tubal obstruction** (will not help; needs ART) **Mnemonic:** **CHOP** — Clomiphene is the first-line agent for: - **C**yclic anovulation (idiopathic) - **H**ypothalamic–pituitary dysfunction (with normal prolactin/TSH) - **O**vulation induction (first-line) - **P**olycystic ovary syndrome (PCOS) — though metformin is often added ### Dosing and Ovulation Rates - **Standard dose:** 50 mg once daily for 5 days (days 3–7 or 5–9 of cycle) - **Ovulation rate:** 70–80% of cycles - **Pregnancy rate:** 30–40% per cycle (cumulative ~90% by 6 cycles) - **If no ovulation at 50 mg:** Increase to 100 mg, then 150 mg (max 250 mg) ### When to Switch to Second-Line Agents ```mermaid flowchart TD A[Anovulatory woman<br/>Normal prolactin/TSH]:::outcome --> B[Start clomiphene citrate<br/>50 mg daily × 5 days]:::action B --> C{Ovulation achieved?}:::decision C -->|Yes| D[Continue cycles<br/>Monitor for pregnancy]:::action C -->|No| E[Increase dose to 100 mg<br/>Repeat up to 150 mg]:::action E --> F{Ovulation achieved?}:::decision F -->|Yes| G[Continue at effective dose]:::action F -->|No| H[CC-resistant<br/>Switch to gonadotropins<br/>or letrozole]:::action D --> I{Pregnant?}:::decision I -->|Yes| J[Pregnancy achieved]:::outcome I -->|No| K[Reassess after 6 cycles]:::decision ``` **High-Yield:** Approximately 20–25% of anovulatory women are **clomiphene-resistant** (no ovulation despite max dose). These patients require: - **Gonadotropins (FSH ± hCG)** — most effective but requires intensive monitoring - **Letrozole** — emerging alternative with similar efficacy to CC but lower OHSS risk - **Metformin** (if PCOS) — improves CC sensitivity [cite:Jeffcoate's Principles of Gynaecology 8e Ch 13; ASRM Guidelines on Ovulation Induction 2020]